Payment overview · 2025
General Payments
$534.69
23 reported records · 11 companies
Healthcare provider profile · identity verified
Joaquin Reyes, MD
Allopathic & Osteopathic Physicians|Family Medicine · RIVERSIDE, CA · NPI 1295720316
Verified facts
What the public records show
CMS Open Payments records show Joaquin Reyes, MD received $534.69 in general payments during 2025 across 23 reported records.
Abbott Laboratories accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $98.99 | 18.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $87.57 | 16.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.82 | 16.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.64 | 10.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.21 | 8.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.63 | 7.0% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $32.35 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.19 | 5.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.96 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.32 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.01 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $534.69 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $98.99 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $69.34 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.91 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.91 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $46.21 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $32.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 660 | 194 |
| Metformin Hcl | Metformin Hcl | 383 | 111 |
| Losartan Potassium | Losartan Potassium | 332 | 96 |
| Lisinopril | Lisinopril | 285 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 73 |
| Glipizide | Glipizide | 213 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 61 |
| Gabapentin | Gabapentin | 147 | 46 |
| Simvastatin | Simvastatin | 141 | 44 |
| Doxazosin Mesylate | Doxazosin Mesylate | 132 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 40 |
| Benazepril Hcl | Benazepril Hcl | 127 | 36 |
| Carvedilol | Carvedilol | 111 | 35 |
| Alendronate Sodium | Alendronate Sodium | 110 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 33 |
| Januvia | Sitagliptin Phosphate | 89 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | 13 |
| Famotidine | Famotidine | 75 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 30 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 61 | 16 |
| Sertraline Hcl | Sertraline Hcl | 59 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Omeprazole | Omeprazole | 52 | 22 |
| Atenolol | Atenolol | 50 | 15 |
| Eliquis | Apixaban | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 15 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 12 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | 11 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Furosemide | Furosemide | 22 | 11 |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Clonazepam | Clonazepam | 11 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ritonavir | Ritonavir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $534.69 · 23 records | Abbott Laboratories | BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, Ozempic, Repatha, Rybelsus, UBRELVY, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error